• Publications
  • Influence
Massively parallel digital transcriptional profiling of single cells
TLDR
A droplet-based system that enables 3′ mRNA counting of tens of thousands of single cells per sample is described and sequence variation in the transcriptome data is used to determine host and donor chimerism at single-cell resolution from bone marrow mononuclear cells isolated from transplant patients.
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
TLDR
After 5 years of follow-up, continuous treatment of chronic-phase CML with imatinib as initial therapy was found to induce durable responses in a high proportion of patients.
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013.
TLDR
Optimal responders to chronic myeloid leukemia treatment should continue therapy indefinitely, with careful surveillance, or they can be enrolled in controlled studies of treatment discontinuation once a deeper molecular response is achieved.
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet.
TLDR
Imatinib should be continued indefinitely in optimal responders and second-generation TKIs are recommended, followed by allogeneic hematopoietic stem-cell transplantation only in instances of failure and, sometimes, suboptimal response, depending on transplantation risk.
The role of FLT3 in haematopoietic malignancies
TLDR
Exploring the mechanism by which mutations in the FLT3 gene cause uncontrolled proliferation might lead to a better understanding of how cells become cancerous and provide insights for the development of new drugs.
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.
TLDR
The proportion of patients with CML who had a reduction in BCR-ABL transcript levels of at least 3 log by 12 months of therapy was far greater with imatinib treatment than with treatment with interferon plus cytarabine.
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects.
TLDR
A novel allografting approach, based on the use of postgrafting immunosuppression to control graft rejection and GVHD, has dramatically reduced the acute toxicities of allogRAFTing.
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain
TLDR
Suggestions are made for harmonizing the differing methodologies for measuring BCR-ABL transcripts in patients with CML undergoing treatment and using a conversion factor whereby individual laboratories can express BCR -ABL transcript levels on an internationally agreed scale.
Massively parallel digital transcriptional profiling of single cells
TLDR
A droplet-based system that enables 3′ mRNA counting of up to tens of thousands of single cells per sample is described and enables characterization of diverse biological systems with single cell mRNA analysis.
International randomized study of interferon Vs STI571 (IRIS) 8-year follow up: Sustained survival and low risk for progression or events in patients with newly diagnosed chronic myeloid leukemia in
TLDR
CML-CP pts responding to IM had a low overall risk of progression to AP/BC and the safety profile of IM remains unchanged after 8 yr, with no previously unreported AEs identified over the past 36 mo.
...
1
2
3
4
5
...